Aura Biosciences, Inc. (AURA)
Develops targeted cancer drugs using modified virus particles to attack solid tumors.
$7.05-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+4.6%
The outlook
AURA is trading at $7.05, positioned midway through its 52-week range and above both its 50- and 200-day averages. Analyst consensus leans strongly bullish, with an average target implying substantial upside from current levels. The stock shows technical strength relative to recent price action.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 5 analysts
Price trendAbove its 50- & 200-day averages
52-week range48% of the way from its 52-week low to high
Price targetAvg target +167% vs current price
Analyst price target
~12-month · 5 analysts$18.80average target+166.7% vs now
Now $7.05
Low $15.00High $24.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$729.2M
52-wk high
$9.54
52-wk low
$4.73
50-day avg
$6.99
200-day avg
$6.36
Trailing P/E
—